Markets and share prices

Biogen Inc

07 May 2026 16:17 PM

20 minutes delayed

Value/last trade

191.20 USD

0.27%

0.52

Day high/low

192.10 - 189.58

Ex-Dividend Date

Dividend Pay Date

Rolling 12m Net Div

NASDAQ

Biogen Inc

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Invest with Davy Select

Davy Select is designed for investors at all stages of their financial journey, who are comfortable making their own investment decisions without advice.

Self-directed investing

© Morningstar. All Rights Reserved. The information, data, analyses and opinions contained herein (1) include the confidential and proprietary information of Morningstar, and/or its content providers; (2) may include, or be derived from, account information provided by your financial advisor which cannot be verified by Morningstar; (3) may not be copied or redistributed; (4) do not constitute investment advice offered by Morningstar; (5) are provided solely for informational purposes and therefore are not an offer or recommendation to buy or sell a security; and (6) are not warranted to be correct, complete or accurate. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, this information, data, analyses or opinions or their use.

Warning: Past performance is not a reliable guide to future performance. The value of investments and of any income derived from them may go down as well as up. You may not get back all of your original investment. Returns on investments may increase or decrease as a result of currency fluctuations.